<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031992</url>
  </required_header>
  <id_info>
    <org_study_id>TAHHT</org_study_id>
    <secondary_id>141CHC9008-001</secondary_id>
    <nct_id>NCT01031992</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)</brief_title>
  <acronym>TAHHT</acronym>
  <official_title>Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia GmbH, Erlangen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with
      frequent nosebleeds in the majority of cases. Several reports in the literature support the
      use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the
      study are to test if Tranexamic acid taken orally can

        1. improve anemia (lead to an increased hemoglobin level)

        2. reduce nosebleeds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of hemoglobin level within the phases.</measure>
    <time_frame>Beginning and end of each 3 months period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean epistaxis score (daily duration multiplied by mean subjective daily intensity)</measure>
    <time_frame>Measured once a day during each 3 months period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid first, than placebo</intervention_name>
    <description>For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First placebo, than Tranexamic acid.</intervention_name>
    <description>First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated.

        Exclusion Criteria:

          -  pregnant,

          -  minor,

          -  had an increased risk of thrombotic events (history or signs of cerebrovascular
             events, cardiac arrhythmias, biochemically increased coagulation parameters),

          -  renal insufficiency,

          -  a history of massive hematuria or defects of color vision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urban W Geisthoff, Priv.-Doz. Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Faculty of the University of the Saarland and Hospitals of the City of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätskliniken des Saarlandes, HNO-Abteilung</name>
      <address>
        <city>Homburg</city>
        <state>Saar</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>December 12, 2009</last_update_submitted>
  <last_update_submitted_qc>December 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Universitätskliniken des Saarlandes</name_title>
  </responsible_party>
  <keyword>Hereditary hemorrhagic telangiectasia</keyword>
  <keyword>Rendu-Osler-Weber syndrome</keyword>
  <keyword>Epistaxis</keyword>
  <keyword>Nosebleeds</keyword>
  <keyword>Anemia</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Antifibrinolytics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

